ASX Announcement

30 November 2020

Antisense Therapeutics closes SPP oversubscribed

Antisense Therapeutics Limited (ASX: ANP | US OTC: ATHJY | FSE: AWY) is pleased to announce the successful completion of its Share Purchase Plan (SPP), which was launched on 18 November 2020 targeting $1 million and closed oversubscribed on 26 November 2020.

As a result of the oversubscription, the Company will conduct a scale-back of applications in accordance with the terms of the SPP. The Company has resolved to accept $1.2 million in applications for the issue of 12,000,000 shares under the SPP. It is expected that new shares will be issued and allotted by Wednesday, 2 December 2020. As per standard SPP process, refunds will be processed by the company's share registry Boardroom Limited as soon as possible.

The Company thanks shareholders who participated in the SPP for their strong support. The SPP completes the two-part capital raising, which in total raised $8.5 million via a placement to institutional, professional and sophisticated investors and the SPP, both closing over-subscribed.

This announcement has been authorised for release by the Managing Director.

For more information please contact:

Antisense Therapeutics
Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries
Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.